Journal article
Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation
Abstract
PurposeChemoprevention with a selective estrogen receptor modulator (tamoxifen or raloxifene) is a non-surgical option offered to high-risk women to reduce the risk of breast cancer. The evidence for tamoxifen benefit is based on trials conducted among predominantly postmenopausal women from the general population and on studies of contralateral breast cancer in women with a pathogenic variant (mutation hereafter) in BRCA1 or BRCA2. Tamoxifen …
Authors
Kotsopoulos J; Gronwald J; Huzarski T; Aeilts A; Randall Armel S; Karlan B; Singer CF; Eisen A; Tung N; Olopade O
Journal
Breast Cancer Research and Treatment, Vol. 201, No. 2, pp. 257–264
Publisher
Springer Nature
Publication Date
September 2023
DOI
10.1007/s10549-023-06991-3
ISSN
0167-6806